Lipigon Pharmaceuticals AB (publ)
SSTO:LPGOShare Statistics
As of December 31, 2025, Lipigon Pharmaceuticals AB (publ) has 605.93M shares outstanding.
| Shares Outstanding | 605.93M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | -0.12 |
| P/OCF Ratio | -0.11 |
Financial Position
As of December 31, 2025, Lipigon Pharmaceuticals AB (publ) maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.01 |
| Quick Ratio | 2.67 |
| Interest Coverage | -87.78 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -244.26, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -244.26 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -856.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -907.87, meaning Lipigon Pharmaceuticals AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -907.87 |
| FCF Yield | -856.59 |
Stock Splits
Lipigon Pharmaceuticals AB (publ)'s most recent stock split took place on March 31, 2023 with a 19:23 split ratio.
| Last Split Date | 3/31/2023 |
| Split Ratio | 19:23 |
Scores
As of December 31, 2025, Lipigon Pharmaceuticals AB (publ) has an Altman Z-Score of -26.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.45 |